Docetaxel is a new taxoid which is currently tested in phase III
clinical trials. In preclinical exvaluation. docetaxel w-as found to hax-e a broad spectrum of efficacx (Van Oosterom et al. 1995) . It exhibits hiah lexels of activitv in both first-and second-line breast cancers. including anthrac -cline-resistant neoplasms and nonsmall-cell lung cancers. Howexer. wxithin a aiven indication. not all patients respond to therapy (Bisserx et al. 1991 (Bisserx et al. . 1995a (Bisserx et al. . 1995b ).
Taxoids. represented by docetaxel (Taxotere) and paclitaxel (Taxol) . haxe the propertx of increasinc microtubule stabilitx to lexels incompatible with normal cell metabolism. P-Tubulins are thought to be the major targets of these drugs (Combeau et al. 1994) and. consequently. several prexvious studies have reported alterations in the expression level of ,B tubulins in cell lines resistant to paclitaxel. Jaffrezou et al (1995) reported the oxerexpression of 5-tubulin (class IVa) in cells derixed from an er-throleukaemic cell line (K562) that w-ere selected for their resistance to paclitaxel. Haber et al (1995) found increased lexels of MP32-tubulin in a series of paclitaxel-and docetaxel-resistant J774.2 cell lines. However. the formal implication of tubulin oxerexpression in resistance to taxoids has not been firmlx established.
In addition. it has been show-n that taxoids. as well as other microtubule-damaging drugs. are able to induce Bc12 phosphorylation and apoptosis in cancer cells. Bc 12 has thus been defined as the -uardian of microtubule intet'itx- (Haldar et al. 1997) .
We have identified responsixe. refractory and resistant model tumours w ithin breast and pancreatic cancers. Refractorx tumours do not respond to therapy (innate resistance). whereas the resistant ones are neoplasms that initially responded to therapy and then acquire resistance to the agent (Bisserx et al. 1991 (Bisserx et al. . 1995a (Bisserx et al. . 1995b analy ses A-ere performed according to protocols described prexiously (Bissery et al. 1991 (Bissery et al. . 1995a (Bissery et al. . 1995b The primers used to amplify the different M>-tubulin isoforms were those described by Haber et al ( 1995) . w-ith the exception of the rexerse primer for MfVt-tubulin. Another specific forward primer for this tubulin (TuB4F*) w xas used to confirm the results discussed belowx. The expected amplicon lengths for M1-tubulins were 146. 171. 145. 572 and 194 from M1l to MB5-tubulin respectixely.
Non-competitixve RT-PCR w-as performed on a Perkin Elmer thermal cycler using the following conditions: for Tau and Cl Inh. 5 min at 94 C then 1 min at 94 C. 1 min at 58 C and 1 min at 72-C for a number of cycles that wxill be indicated w-hen necessarfollow-ed by a final extension step for 10 min at 72:C: for MAP2.
MAP4 and all tubulins. 5 min at 94 C then 30 s at 95 C. 30 s at 55-C and 30 s at 72'C for a number of cvcles that A-il be indicated %x-hen necessarv. followed by a final extension step for 10 min at 72'C.
Quantification of RT-PCR products
In order to achieve an accurate quantification of mRNA. (Riou et al. 1994) . Docetaxel is a schedule-independent drug (Bisser-et al. 1991 (Bisser-et al. . 1995b ) that was found to be clearly active on three out of four mammaix tumours (the murine MA 16/C. MA13/C and the human Calc 18) and one out of tx o murine pancreatic tumours (P03 . w-ith a high rate of complete tumour regressions of advanced-stage disease (100%7c for MA16/C. 60%7 NMA13/C and 83%e for P03) ( Table 2) . Two of the murine tumour models w-ere found to be refractory to docetaxel. the mammarv MA44 and the pancreatic P02. when treated at an early stage (Table 1) . It is interesting to note that P02 is also refractors to docetaxel-unrelated drugs (Table 1) . Howexver. the P-glycoprotein (involved in producing a multidrug resistance phenotype: Arceci et al. 1993) has not been shown to be relex-ant for this model (Kessel and Corbett. 1985: Priebe et al. 1992 ).
Analysis of tubulin expression in the murine tumours
The RT-PCR analysis of the expression of tubulin isotypes show-ed no differences in the mRNA levels correspondinc to tubulins M132.
MP3 and M05 among the different tumours. when Mcl-and
Mat2-tubulins w-ere taken as a reference for the quantification. In contrast. the sensitix e tumours w-ere characterized by higher lex els aT/C (0o). for solid tumours = 100 x median tumour weight of the treated/median tumour weight of the controls. nT-C (days) = median time in days required for the treatment group T and the control group C tumours to reach a predetermined size. :log cell kill = T-C in days/3.32 x tumour doubling time of control mice.
'Actvity rating: i1+++i+. highty active (log cell kill > 2. (Figure 2 ). considered to be neuron specific (Lewis et al. 1986 ). was also expressed in these non-neural tissues. As shown in Figure 2 . U12915 and U12914) expressed in the liver (Kenner et al, 1994) and two other isoforms (M18775 and M18776) known to be expressed in mouse brain ). Interestingly. docetaxel-sensitive tumours showed higher levels of Tau mRNA (Figure 2 Figure 4A and B, the higher levels of Tau-like polypeptides in the sensitive mammary adenocarcinomas consisted mainly of a species of high molecular weight (125 kDa). However, in the refractory tumour (MA44). some polypeptides located towards the higher molecular weights within the Tau region were more abundant than in the sensitive neoplasms. By using a monoclonal antibody directed against brain MAP2. the presence of related polypeptides was established in the different murine tumours. As shown in Figure 5A -C, the classical 300-kDa MAP2 was not found. probably because of its proteolytic fragmentation. and the relative amounts of the different polypeptides British Joumal of Cancer (1998) 78(7) Analysis of microtubular proteins in human-derived tumours sensitive to, or with acquired resistance to, docetaxel Mammary tumours of human origin either sensitive to (Calc 18) or resistant to (Calcl8/17XT) docetaxel were also analysed after extraction of proteins with a detergent-rich RIPA buffer ( Figure 6 ). (Lee et al. 1984 : Cowan et al. 1986 (Fromes et al. 1996) . In addition, it is known that the ectopic expression of Tau in non-neural cells increases microtubule stabilization (Lee et al. 1992) . Furthermore, different levels of Tau proteins may alter the ratio of polymerized versus non-polymerized tubulin, and it has been shown that lowering the net amount of polymerized tubulin is sufficient to confer taxol acquired resistance (Cabral et al, 1989) . Our data also showed a significant expression of a Tau-related polypeptide. of about 125 kDa. in the sensitive tumours. which may correspond to the high molecular weight isoform found in the mature peripheral nervous system and therefore may be involved in modulating microtubule stability (Couchie et al. 1992) . The shift of several Tau isoforms to the higher molecular weights within the Tau region in the murine refractory tumour MA44 suggests that the state of phosphorylation of these proteins is more important in this tumour (Figure 4 ). Interestingly. highly phosphorylated Tau has a poor capacity to be inorporated in microtubules and may generate unstable structures that are less sensitive to the stabilizing effect of docetaxel (Lindwall and Cole. 1984; Correas et al. 1992) . When comparing Figures 3 and 4 . it can be seen that several Tau-related polypeptides present in the murine refractory tumours were extracted in detectable amounts only upon using a detergent-enriched REPA buffer. It is possible that cytoskeletal proteins of tumoral epithelial cells are not easily extractable because of the abundance of a fibrous and dense stroma surrounding tumoral cells. It is also likely that several Tau isofonns may aggregate by a self-association reaction similar to that described by de Ancos et al ( 1993) .
A higher level of several MAP2-related polypeptides was detected in the docetaxel-sensitive tumours, particularly a fragment of approximately 36-38 kDa. Interestingly. the 36-kDa tubulin-binding domain of MAP2 has some Tau-like properties and has been shown to modulate the effect of some antimicrotubular drugs such as vinblastine (Fellous et al. 1994 ).
We have also investigated the behaviour of microtubule components in two types of tumours derived from a human breast carcinoma: Calc 18. sensitive to docetaxel. and Calc 1 8TfXT. resistant to the drug. The latter came from a cell line overexpressing the MDRJ gene and veraparnil was able to reverse its docetaxel resistance (Riou et al, 1994) . Consequently. the tumour Calcl8/1XT moderately expressed the P-glycoprotein (data not shown). In spite of this. we showed that frtubulin was less abundant in the resistant neoplasm when using a-tubulin to normalize for the amount of microtubule proteins. This may reflect the decreased level of >-tubulin mRNAs observed in the Calc 18/XT cell line with respect to the parental Calc18 (Riou et al. 1994) . Interestingly, decreased levels of tubulins have been shown to confer resistance to taxol in certain cellular models (see Cabral et al. 1989 ). Using our polyclonal antibody directed against Tau (Vantard et al. 1991) . we also observed differences in the expression of Tau-related polypeptides in both types of tumours. The monoclonal antibody Tau 1. sensitive to the phosphorylation state of the protein, revealed striking differences between the neoplasms. but a certain variability that was noticed in the results was probably due to uncontrolled changes of the Tau phosphorylation state. Immunohistochemical studies demonstrated that the polypeptides recognized by Taul were expressed mainly in the sensitive tumours and the epithelial malignant cells (data not shown).
Although the nature of the decreased docetaxel sensitivity of the tumours refractory (innate resistance) and resistant (acquired resistance) to the drug are conceptually different, both types of tumour displayed differences in the expression and modification of some Tau isoforms. However, other alterations of microtubular components specific to each type of tumour may also contribute to produce the resistant phenotype. i.e. lower levels of J-tubulin in Calc I 8frXT.
In conclusion, the levels of several Tau isoforms in both murine and human-derived freshly explanted docetaxel-sensitive tumours and. to a lesser extent. the mRNA levels for MV-tubulin in the murine tumours can be regarded as markers of sensitivity to the drug. From a practical point of view. the finding that some Tau isoforns are not only present in different amounts but also probably in different phosphorylation states. may allow the use of specific antibodies on tumour biopsies and may help decide upon the worth of a taxoid treatment. These findings are now being evaluated on a broader panel of human tumour samples. Tau expression and docetaxel sensitivi in vivo 877
